What if one of the oldest acts of personal care — immersing the body in water — could move with the person instead of confining them to a bowl, a tub, or a clinic station? The answer is patented. The product is ready. Three SKUs. 200 units. Dropping now.
"What if one of the oldest acts of personal care — immersing the body in water — could move with the person instead of confining them to a bowl, a tub, or a clinic station?"
The answer took eight years to build. SOKY is not just a glove or a sock. It is a platform for turning simple, ancient inputs — water, salts, botanicals, warmth, time, and now precision formulations and next-generation peptide applications — into localized rituals people can actually keep. The tools were always there. We removed the reason not to begin.
The IP is issued. The manufacturer is ready. The team is distributed across three continents and committed. HandSOKY_B_M_000, HandSOKY_B_M_001, and HandSOKY_B_M_002 are dropping now. What remains is the execution of a focused, community-first launch — prove the product, earn the trust, then scale.
Website live. Campaign assets deployed. Three SKUs available — HandSOKY_B_M_000 (Research Access), HandSOKY_B_M_001 (Core), HandSOKY_B_M_002 (Travel System) — 200 units total. Sell through. Generate community trust. Open waitlist for Batch 2. Community first. The ask follows.
Two investors — Sosimo Roman ($150K) and Seymour Everett of Everett Dorey LLP ($30K) — have already committed. Additional capital is sought to complete the launch, not to fund a hypothetical future.
NM Thera was born from the founder's struggle with palmar hyperhidrosis — sweaty hands that made even simple interactions difficult. The moment that changed everything was when a little girl asked to hold his hand, and he had to say no. That small but painful experience lit the spark for what would become eight years of development.
"Care for the hands is care for everything the hands make possible. When we restore circulation to tired hands, we restore the capacity to build. When we return sensation to numb feet, we return a person to their own body."— NM Thera Manifesto, 2026
The options for treating conditions like palmar hyperhidrosis have barely evolved in decades. Existing treatments are clunky machines, expensive procedures, or routines so inconvenient that most people give up. SOKY was built to be something different — something that fits into daily life, that earns its place in the morning routine, that travels with the person.
The ritual of soaking has existed in every human culture that left records. The Romans, the Japanese, the Turks, the Koreans — they all understood something that modern medicine largely forgot: that warm water, time, and attention are among the most powerful therapeutic forces available. SOKY is not an invention. It is a remembering — made portable, accessible, and ready for the world we actually live in now.
Mission · Vision · Values
Mission: Provide innovative solutions and compassionate support for people whose skin and health conditions impact their confidence, relationships, or work.
Vision: Restore the simple, human ability to connect — so every person can live with confidence, dignity, and fulfillment.
Values: Innovation · Openness · Connection · Discipline · Humanity
"SOKY supports personal care routines. It is not intended to diagnose, treat, cure, or prevent any disease or condition." Paired with all product descriptions per BSG guidelines.
The oldest therapies are the most democratic: water, minerals, botanicals, warmth, cooling, attention, and a vessel that lets the body stay with them. These are not luxury inputs. They are what is already available. SOKY's work is to maximize what people already have access to — and remove every reason not to begin.
The Ritual — Five Steps. Every Product. Always This Order.
The cuff must always be folded inward — into itself to form the watertight/airtight seal. With the cuff folded, pinch and guide your hand in steadily, each finger fully into its sheath, until the opening of the folded cuff rests flush around the wrist — no kinks, no gaps, no distortions. This step is non-intuitive. It is where the product is either used correctly or not at all.
The Engineering Core — Why the Seal Works
Every prior wearable immersion device failed at the same point: when the garment moves, hydrostatic pressure peels the seal away. SOKY inverts this failure mode entirely. The inversion frustal cuff — a tapered, thin-walled elastomeric shell — folds inward at the wrist or ankle, creating an axial overlap region. When internal pressure increases — the user lifts their hand, fluid shifts — liquid enters the pocket and presses the inner layer more firmly against the skin. The more pressure builds, the tighter the seal becomes. No clamps, no adhesives, no power.
The Universal Port Interface
One interface. All modalities. Interchangeable caps enable: sealed soak, fill and drain, circulation, iontophoresis and electrotherapy, temperature and pressure sensing, ultrasound and photobiomodulation, gas delivery, and additive reservoirs for peptide and botanical solutions. Model F (passive OTC) and Model E (clinical electro) are the same garment — a different cap attached.
Platform Expansion Arc
Hands → Feet → Arms → Legs → Knees → Elbows → Pelvic → Custom zones. Each new body zone unlocks incremental market without new manufacturing infrastructure — only new garment molds. The same ritual. The same port. The same knowledge library.
What goes into the water defines the ritual. SOKY's enhancement system spans thermal modes, electrotherapy, botanical soaks, mineral salt formulations, concentrated active ingredient delivery, and — a significant emerging frontier — topical peptide soaks for precision skin and transdermal applications.
The Volume Advantage — Concentration by Design
Every SOKY garment holds a fraction of the fluid volume required by a conventional foot bath or hand soak basin. This is not a limitation — it is a delivery mechanism. A standard antifungal dose formulated for a two-liter foot bath, used in a SOKY sock containing only a cup of water, achieves a significantly higher active concentration at the treatment site with no increase in ingredient cost. The same logic applies across menthol, salicylic acid, urea, camphor, lidocaine analogs, and botanical extracts.
At the clinical tier, Rx-formulated soak packs open a reimbursement and compounding pharmacy partnership pathway. Users can reduce ingredient use to match conventional concentrations, or maintain standard dosing to access concentrations previously unavailable outside a clinical setting.
Topical Peptide Soaks — A Precision Frontier
Sealed occlusive environments increase stratum corneum hydration by 300–400%, dramatically enhancing the permeation of topically applied agents. This positions SOKY as a delivery vehicle for collagen-stimulating peptides (Argireline, Matrixyl), barrier-repair peptides for eczema, growth factor peptides for post-surgical recovery, copper peptides for circulation support, and neuropeptide solutions for hyperhidrosis management. Target: $35–$65/pack, 2–4 packs/month. Estimated gross margin: 75–82%.
Every garment sold is a distribution channel for recurring consumable revenue. Mineral salts, botanical herb blends, emollient oil packs, antifungal solutions, concentrated active formulations, iontophoresis mineral concentrates, and precision peptide packs — all formulated for the SOKY liquid environment, all reordered on subscription or replenishment. This is the flywheel that converts a hardware platform into a lifetime value engine.
Early Proof Points
- 109 out of 130 prospective users expressed interest — 83.8% pre-launch conversion rate
- 5 clinicians actively engaged, protocol conversations already underway
- LOI for $70,000 in initial annual orders from a leading footcare distributor
- Dr. Craig Heller (Stanford) joins as Research Advisor — world authority on palmar AVA thermoregulation
- Seymour Everett (Everett Dorey LLP, OC) joins as Investor and Strategic Legal Advisor
- Sosimo Roman presses forward $150K — turnkey production and packaging in ready state
First Drop — HandSOKY_B_M_000 · 001 · 002
Community is built before the ask is made. A launch audience assembled around demonstrated quality is a better asset than any ad spend. Kickstarter and WeFundr remain on the roadmap — activated from a warm base, not a cold start. The first drop is not the campaign. It is the proof that earns the right to run one.
SOKY's product development runs three parallel tracks — each with its own cost structure, timeline, and manufacturing partner. All three share the same garment platform, IP foundation, and universal port interface. The first drop is a single mold. One cavity. One size. Everything downstream is unlocked by what that first mold proves.
- Hand SOKY Medium (Mold 1)
- Foot SOKY Medium (Mold 2)
- Establishes manufacturing relationship
- De-risks triple-cavity investment
- Four triple-cavity molds
- M cavity supersedes validation tools
- $200K milestone
- Unlocks eczema wet-wrap protocols
- Feeds pediatric RLP pipeline
- Each zone: 3-model cascade
- Sitz SOKY at Mold 19
- $800K buffered milestone
Named Research Projects
Design Experiments
SOKY OTC (e-commerce, Amazon, retail) · SOKY Rx (clinical B2B, insurance reimbursement) · SOKY Plus (recurring consumables including peptide packs) · Wellness App (subscription tiers) · Licensing & IP partnerships · Data monetization from anonymized research · Content sales and educational licensing · Mobile app advertising and sponsorship · Clinical protocol licensing to healthcare institutions
NM Thera's IP portfolio is a material competitive moat. The issued patent covers the core mechanism with 15 claims spanning the garment, seal, iontophoresis circuit, and mobility-in-use. The pending platform patent expands coverage to the full geometry family. The trademark portfolio protects the brand namespace across all product lines and markets.
| Ref | Title & Number | Status | Scope | Moat Depth | Valid |
|---|---|---|---|---|---|
| IP 01 | Method and Apparatus for Treatment of Hyperhidrosis US 11,602,631 B2 NM Therapeutics, LLC · Kenny Pham & Jennifer Nguyen Filed June 2018 · Issued March 14, 2023 · A61N 1/325 |
Issued · Active | Water-filled glove, inversion cuff seal, iontophoresis circuit, mobility-in-use. 15 claims. | 2043 | |
| IP 02 | Method and Apparatus for Localized Immersion Provisional filed December 2025 |
Pending | Full frustal profile family — conical, parabolic, hyperbolic, superelliptical, spline-defined, anatomically conformal. Full body-zone and modality spectrum. | Pending | |
| IP 03 | Trademark: "NM Thera" | Registered | Brand name across the full product and platform namespace. | Active | |
| IP 04 | Trademark: "SOKY" & Water Drop Logo Mark | Pending | Product name and visual mark — the visual cornerstone of the brand system across all lines. | Pending |
The pending platform patent claims the full family of frustal geometries. No competitor can replicate the core pressure-responsive sealing mechanism by varying taper angle or cross-sectional shape. This is not a narrow pharmaceutical-style patent — it covers the entire geometric design space of the cuff. The moat widens materially as prosecution continues.
Core Team
Advisors
Investor-Partners
Seymour Everett holds 10% equity and serves as legal advisor. Counsel is invested in the outcome. Everett Dorey handles corporate structure, IP prosecution, equity documentation, regulatory pathway legal support, and ongoing governance.
Dr. Heller's research on palmar AVA vasculature and thermoregulation is directly relevant to SOKY's mechanism and therapeutic claims. His science is the evidentiary foundation of the platform's clinical positioning and central to the research product track.
ISO 13485 certified. Turnkey silicone compression molding from tooling through fulfillment. Relationship established, first mold complete, production scales on confirmation. ~$10K per new commercial mold. No parallel QMS buildout needed at current stage.
Breakthrough silicone 3D-printing. Research SKUs at ~$2,500 per toolpath versus $12,000+ traditional tooling. RLP prototypes feed directly into TopSheng's validated commercial pipeline.
Regulatory Pathway
| Track | Classification | Pathway | Status |
|---|---|---|---|
| SOKY OTC — Model B / Model F | Class I | 510(k) exempt — passive thermotherapy | Market entry ready |
| SOKY Pro / Rx — Model E | Class II | 510(k) notification — iontophoresis, TENS, EMS | MFG ISO 13485 ready / FDA action plan ready |
| EU / Canada | CE / MDL | Conformity assessment / CMDCAS | Post-US launch / Global Launch |
| Quality Management | ISO 13485 | Via TopSheng (active) | No parallel QMS buildout required |
The therapeutic modalities SOKY delivers — balneotherapy, hydrotherapy, iontophoresis, occlusive wet-wrap, contrast bathing — are among the most studied localized care approaches in medicine. SOKY's contribution is not the science. It is making that science accessible, repeatable, and portable for the first time.
Iontophoresis: Tap water iontophoresis produces 80%+ sweat reduction in controlled clinical studies. (Kreyden OP, J Cosmet Dermatol, 2004; Pariser & Ballard, Arch Dermatol Res, 2019.) Occlusion: Sealed occlusive environments increase stratum corneum hydration by 300–400%, dramatically enhancing topical agent permeation. (International Journal of Pharmaceutics.) Balneotherapy / RA: Significant, sustained reduction in pain and disability vs standard care. (Cochrane Database Syst Rev.) Atopic Dermatitis: Dead Sea mineral baths produce statistically significant SCORAD improvement sustained at 3-month follow-up. Adherence: 68% of patients abandon home immersion routines within 30 days — primary reason: setup friction. SOKY's portable format shows a documented 36-point improvement in 30-day adherence.
Clinical Dispensing Opportunity
Physical Therapists, Occupational Therapists, Dermatologists, and Podiatrists represent an immediately accessible B2B channel. A 15-patient dispensing program generates an estimated $15,600 in supplemental annual revenue per clinic — a meaningful number for a practitioner, a recurring revenue stream for NM Thera, and a trust signal that compounds into consumer referrals.
Conditions Addressed
Palmar & Plantar Hyperhidrosis · Atopic Dermatitis / Eczema (including pediatric) · Post-Surgical Hand & Foot Recovery · Rheumatoid & Osteoarthritis · Peripheral Vascular Disease / Diabetic Neuropathy · Psoriasis · Post-Exercise Recovery · Plantar Fasciitis · Wound Healing (SOKY Clinical Track)
SOKY enters the market as the only wearable soak platform in existence. Every market SOKY addresses was previously served by a stationary format. The opportunity is not to take share from an existing product. It is to redefine the category. At 1% SAM penetration, NM Thera projects annual revenues of $50–$100M by Year 10.
| Market | TAM | SOKY Angle |
|---|---|---|
| Hand & Foot Care | $12.2B | First mover. Disrupts the $2B foot spa bath market entirely. |
| Hyperhidrosis | $646M | Issued patent US 11,602,631 B2 covers wearable iontophoresis through 2043. |
| Wellness | $1.5T | Don · Fill · Seal · Soak · Drain maps directly onto fastest-growing wellness ritual behaviors. |
| Wearable Medical Devices | $34B → $120B | 28% CAGR 2023–2030. Only wearable immersion platform in this category. |
| Eczema & Skin Care | $145B | Pediatric wet-wrap (Track 2). Peptide packs for barrier repair and anti-aging. |
| Sports Medicine | $5.9B → $8.4B | Contrast therapy, post-injury immersion, sleeve family formats. |
| Physical Therapy | $39.3B | Clinical dispensing program. PT/OT practitioners as referral nodes. |
| Anti-Aging / Precision Skincare | $23.4B+ | SOKY Plus peptide soak line — clinically-informed skincare delivery. |
PowerDot was acquired by Therabody for approximately $34M in 2021 — a single-modality device with no consumable flywheel and a narrower product scope than SOKY at equivalent stage. Potential acquirers across the SOKY platform: Therabody, Johnson & Johnson, Medtronic, Abbott, Zimmer Biomet, Samsung Health.
Total raised: $180K ($150K Sosimo Roman + $30K Seymour Everett). Runway: approximately one month remaining. Revenue generation from HandSOKY_B_M_001 and HandSOKY_B_M_002 is the immediate operational priority.
Phase Structure
- Website live · 3 SKUs available
- 3LINX fulfillment SOP confirmed
- Campaign assets deployed
- Waitlist open for Batch 2
- Foot SOKY Medium mold
- SOKY Plus consumable SKUs
- Kickstarter / WeFundr launch
- Peptide packs introduced
- Full adult Hand + Foot lineup
- Model E (Ionto) via RLP
- Clinical dispensing partnerships
- 510(k) preparation for Model E
Unit Economics
| SKU | Price | COGS (est.) | Gross Margin |
|---|---|---|---|
| HandSOKY_B_M_001 — Hand SOKY | $85 | $27–$29 | ~65–68% |
| HandSOKY_B_M_002 — Travel System | $150 | $35–$42 | ~72–77% |
| SOKY OTC full range | $85–$175 | $16–$27 | 65–80% |
| SOKY Plus — Salts / Botanicals | $18–$35 | $4–$8 | 75–85% |
| SOKY Plus — Peptide Packs | $35–$65 | $8–$14 | 75–82% |
| SOKY Rx / Model E | $750–$1,000 | TBD | High |
Valuation History — How Value Was Built: 2016–2026
Current Valuation — $3.2M Base Case
Not a founder estimate. The output of three complementary methods, triangulated against comparable transactions and discounted against execution risk in a macro-aware framework.
$3.13M weighted average → rounded to $3.2M base case. (35% × $1.85M) + (35% × $3.5M) + (30% × $4.2M) = $3.13M.
Scenario Analysis
Valuation Trajectory
| Period | Stage | Revenue | Multiple | Valuation | vs. Today | Comparable |
|---|---|---|---|---|---|---|
| March 2026 | Pre-revenue · Launch | — | Asset basis | $3.2M | — | PowerDot pre-seed |
| Year 2 (2028) | First revenue scale | $3.65M | 3× | $12M | 3.75× | HoMedics early |
| Year 3 (2029) | Full OTC lineup | $20.4M | 3.5× | $71M | 22× | TheraIce scale |
| Year 5 (2031) | SOKY Rx + App | $48.1M | 4× | $193M | 60× | HyperIce comparable |
| Year 10 (2036) | Full platform | $72M | 5× | $361M | 113× | Therabody Amazon parity |
Return Profile at a Glance
Risk Landscape — Plain Language
What We Are Looking For
Modest operational capital to ensure the first drop executes cleanly — campaign assets, fulfillment costs, runway extension through initial sell-through. Investors who enter now receive the most favorable terms in the company's history. The ask is small. The entry multiple is 113× at base case.
$15,000 unlocks the Foot SOKY single-cavity mold — a second complete product family, three new SKUs, a second body zone, and the opening of the footcare channel. An additional $10,000–$15,000 accelerates size expansion into triple-cavity tooling.
NM Thera actively seeks investors whose networks accelerate distribution, clinical validation, or retail presence. A pathway to Therabody, HyperIce, a medical device distributor, a professional sports recovery network, or a practitioner channel creates value that exceeds the dollar amount of the check by a significant multiple.
"NM Thera is priced at $3.2M at a moment when the option value of the platform — a patented, defensible, no-direct-competitor wearable soak system positioned across a $597B TAM — is substantially larger than the current price implies. The runway constraint creates a near-term execution risk that is real but not structural. An investor entering at $3.2M today with a ten-year hold and $361M exit achieves a ~113× return on base case, or ~200× on the bull case. In a volatile macro environment where most early-stage investments are speculative narrative plays, NM Thera has an issued patent, a validated manufacturing partner, documented clinical evidence, and a signed LOI as tangible anchors. This is an asymmetric bet worth taking at the right check size."
"We are building this not as a product company but as a proof of concept. A demonstration that health technology can be humane, accessible, repairable, and financially sustainable at the same time."— NM Thera Manifesto, 2026
Confidentiality Notice. This document contains proprietary and confidential information belonging to NM Therapeutics, Inc. It is provided solely for the use of the named recipient and may not be reproduced, disclosed, or distributed without prior written consent. All financial projections are forward-looking and subject to material risks and uncertainties.
NM Therapeutics, Inc. · kenny@nmthera.com · 714-782-2843 · nmthera.com · Eastvale, CA
SOKY supports personal care routines. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition.